Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3250826 | 0.80 | ALDH1A1 (0.58) | ALDH1A1LMNASMN1; SMN2MAPTTP53 | |
| SCHEMBL3010244 | 0.78 | THRB (0.54) | ALDH1A1LMNASMN1; SMN2MAPTTP53 | |
| SCHEMBL3003897 | 0.78 | ALDH1A1 (0.52) | ALDH1A1LMNASMN1; SMN2MAPTTP53 | |
| SCHEMBL2993898 | 0.78 | ALDH1A1 (0.56) | ALDH1A1LMNASMN1; SMN2MAPTTP53 | |
| SCHEMBL2992365 | 0.78 | ALDH1A1 (0.51) | ALDH1A1LMNASMN1; SMN2MAPTTP53 | |
| SCHEMBL4258306 | 0.78 | ALDH1A1 (0.51) | ALDH1A1LMNASMN1; SMN2MAPTTP53 | |
| SCHEMBL3006646 | 0.76 | NPSR1 (0.57) | ALDH1A1LMNASMN1; SMN2MAPTTP53 | |
| SCHEMBL3004302 | 0.76 | KMT2A (0.52) | ALDH1A1LMNASMN1; SMN2MAPTTP53 | |
| SCHEMBL3000251 | 0.75 | ALDH1A1 (0.48) | ALDH1A1LMNASMN1; SMN2MAPTTP53 | |
| SCHEMBL3243875 | 0.75 | MAPT (0.63) | ALDH1A1LMNASMN1; SMN2MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045428-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-8716319-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130324525-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20100197684-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD PALO ALTO, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| WO-2010002483-A1 | OPTIONALLY CONDENSED DIHYDRO PYRIDINE, DIHYDROPYRIMIDINE AND DIHYDRO PYRANE DERIVATIVES ACTING AS LATE SODIUM CHANNEL BLOCKERS | CV THERAPEUTICS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| US-20090181986-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | CV THERAPEUTICS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090012103-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. | 2009-01-08 | — | — | US | disclosed |
| WO-2009006580-A1 | OPTIONALLY CONDENSED DIHYDROPYRIDINE, DIHYDROPYRIMIDINE AND DIHYDROPYRANE DERIVATIVES ACTING AS LATE SODIUM CHANNEL BLOCKERS | CV THERAPEUTICS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197684-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | NQO1, GPR119, GLP1R | ALDH1A1 274/4885LMNA 738/4885SMN1; SMN2 1739/4885 |
| US-20130324525-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | NQO1, GPR119, GLP1R | ALDH1A1 274/4885LMNA 738/4885SMN1; SMN2 1739/4885 |
| US-20090181986-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | NQO1, GPR119, GLP1R | ALDH1A1 274/4885LMNA 738/4885SMN1; SMN2 1739/4885 |
| US-20090012103-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | NQO1, GPR119, GLP1R | ALDH1A1 274/4885LMNA 738/4885SMN1; SMN2 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.